In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adcock Ingram Holdings Ltd.

Latest From Adcock Ingram Holdings Ltd.

Adcock Kept Cash Back For Two Major Deals, Prioritizes Partnerships

Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.

Sales & Earnings Strategy

Blitzima A Boost For Adcock As It Scoops Up New Rituximab Patients

South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.

Biosimilars Sales & Earnings

Adcock Ingram Breaks Into Biosimilars With Infliximab

South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.

Biosimilars Launches

Adcock Reports Slight Growth In A ‘Difficult Market’

Adcock has made slight progress despite the effect of the current economic climate in South Africa on consumer spending and behavior.

Sales & Earnings South Africa
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer